Interplay Between TGF-β Signaling and MicroRNA in Diabetic Cardiomyopathy.

Cardiovasc Drugs Ther

Pathophysiology Department, Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hongxiang Street, Hengyang, 421001, Hunan, China.

Published: December 2023

In diabetic patients, concomitant cardiovascular disease is the main factor contributing to their morbidity and mortality. Diabetic cardiomyopathy (DCM) is a form of cardiovascular disease associated with diabetes that can result in heart failure. Transforming growth factor-β (TGF-β) isoforms play a crucial role in heart remodeling and repair and are elevated and activated in myocardial disorders. Alterations in certain microRNAs (miRNA) are closely related to diabetic cardiomyopathy. One or more miRNA molecules target the majority of TGF-β pathway components, and TGF-β directly or via SMADs controls miRNA synthesis. Based on these interactions, this review discusses potential cross-talk between TGF-β signaling and miRNA in DCM in order to investigate the creation of potential therapeutic targets.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-023-07532-2DOI Listing

Publication Analysis

Top Keywords

diabetic cardiomyopathy
12
tgf-β signaling
8
cardiovascular disease
8
interplay tgf-β
4
signaling microrna
4
diabetic
4
microrna diabetic
4
cardiomyopathy diabetic
4
diabetic patients
4
patients concomitant
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!